Cereno Scientific’s novel HDACi CS014 has potential to become an effective antithrombotic therapy in patients with a high risk of thrombotic events as presented at the ASH Meeting
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that new preclinical data suggests that CS014 has the potential to enrich the toolbox of anticoagulant therapies in patients with a high risk of thrombotic events without increasing the risk of bleeding. CS014 is a novel histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator and is in preclinical development as a treatment for thrombosis prevention. The new data was presented at the 65th ASH Annual Meeting & Exposition